Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons

Autor: Jason F. Okulicz, Robert Deiss, Heather S. Pomerantz, James White, Brian K. Agan, Thankam S. Sunil, Anuradha Ganesan, Xiaohe Xu
Rok vydání: 2018
Předmět:
0301 basic medicine
lcsh:Immunologic diseases. Allergy
Adult
Male
medicine.medical_specialty
Herpesvirus 3
Human
viruses
030106 microbiology
Human immunodeficiency virus (HIV)
Short Report
Enzyme-Linked Immunosorbent Assay
HIV Infections
Disease
medicine.disease_cause
Antibodies
Viral
Herpes Zoster
Virus
03 medical and health sciences
Young Adult
0302 clinical medicine
Virology
Internal medicine
Hiv infected
Antiretroviral Therapy
Highly Active
Military
medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
biology
integumentary system
business.industry
Coinfection
Varicella zoster virus
virus diseases
HIV
Viral Load
3. Good health
CD4 Lymphocyte Count
Vaccination
biology.protein
Molecular Medicine
Female
Virus Activation
Antibody
business
lcsh:RC581-607
Varicella-Zoster Virus Antibody
Zdroj: AIDS Research and Therapy
AIDS Research and Therapy, Vol 15, Iss 1, Pp 1-5 (2018)
ISSN: 1742-6405
Popis: Background Varicella-zoster virus (VZV) reactivation is common but difficult to predict in HIV-infected persons. Objective Since qualitative VZV antibodies can determine past VZV disease or vaccination, we evaluated whether quantitative VZV antibody levels over time can predict future zoster. Study design US Military HIV Natural History (NHS) participants with a zoster diagnosis at least 5 years after HIV diagnosis (n = 100) were included. Zoster-negative controls (n = 200) were matched by age, race, gender, and CD4 count at HIV diagnosis. Repository plasma specimens collected at baseline and prior to zoster diagnosis were evaluated using a quantitative anti-VZV ELISA assay. Differences in quantitative VZV levels were analyzed by Wilcoxon Mann–Whitney and Fisher’s exact tests. Results Median CD4 count at HIV diagnosis was similar for cases and controls (535 [IQR 384–666] vs. 523 [IQR 377–690] cells/μL; p = 0.940), but lower for cases at zoster diagnosis (436 [IQR 277–631] vs. 527 [IQR 367–744] cells/μL; p = 0.007). Antiretroviral therapy (ART) use prior to zoster diagnosis was lower for cases (52.0%) compared to controls (64.5%; p = 0.025). Cases had similar mean VZV antibody levels prior to zoster diagnosis compared to controls [2.25 ± 0.85 vs. 2.44 ± 0.96 index value/optical density (OD) ratio; p = 0.151] with no difference in the change in antibody levels over time (0.08 ± 0.71 vs. 0.01 ± 0.94 index value/OD per year; p = 0.276). Conclusion Quantitative VZV antibody levels are stable in HIV-infected persons and do not predict zoster reactivation. Low CD4 count and lack of ART use appear to be better predictors of future zoster diagnosis.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje